1. Academic Validation
  2. A Non-Competitive Inhibitor of VCP/p97 and VPS4 Reveals Conserved Allosteric Circuits in Type I and II AAA ATPases

A Non-Competitive Inhibitor of VCP/p97 and VPS4 Reveals Conserved Allosteric Circuits in Type I and II AAA ATPases

  • Angew Chem Int Ed Engl. 2018 Feb 5;57(6):1576-1580. doi: 10.1002/anie.201711429.
Robert Pöhler 1 Jan H Krahn 2 Johannes van den Boom 1 Grzegorz Dobrynin 1 Farnusch Kaschani 2 Hans-Michael Eggenweiler 3 Frank T Zenke 3 Markus Kaiser 2 Hemmo Meyer 1
Affiliations

Affiliations

  • 1 Molecular Biology I, Centre for Medical Biotechnology, University of Duisburg-Essen, 45117, Essen, Germany.
  • 2 Chemical Biology, Centre for Medical Biotechnology, University of Duisburg-Essen, 45117, Essen, Germany.
  • 3 Medicinal Chemistry DA and Translational Innovation Platform Oncology, Global R&D, Healthcare, Merck KGaA, Frankfurter Str. 250, 64293, Darmstadt, Germany.
Abstract

AAA ATPases have pivotal functions in diverse cellular processes essential for survival and proliferation. Revealing strategies for chemical inhibition of this class of enzymes is therefore of great interest for the development of novel chemotherapies or chemical tools. Here, we characterize the compound MSC1094308 as a reversible, allosteric inhibitor of the type II AAA ATPase human ubiquitin-directed unfoldase (VCP)/p97 and the type I AAA ATPase VPS4B. Subsequent proteomic, genetic and biochemical studies indicate that MSC1094308 binds to a previously characterized drugable hotspot of p97, thereby inhibiting the D2 ATPase activity. Our results furthermore indicate that a similar allosteric site exists in VPS4B, suggesting conserved allosteric circuits and drugable sites in both type I and II AAA ATPases. Our results may thus guide future chemical tool and drug discovery efforts for the biomedically relevant AAA ATPases.

Keywords

AAA ATPase; VPS4; allostery; drug discovery; p97.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-123872
    99.89%, p97/VPS4B Inhibitor
    p97